FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:297-299 July 17, 2003 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Perspective by Zuger, A. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Thompson, I. M. PubMed Citation

Prostate cancer is the most common non-skin cancer in the United States, the second leading cause of death from cancer among U.S. men, and the seventh leading cause of death in the United States. The number of new cases of prostate cancer, now estimated at more than 220,000 per year, is expected to increase to more than 380,000 by 2025 because of the aging male population. The incidence of prostate cancer and the rate of death due to the disease increase exponentially with age. The other major risk factors for prostate cancer include a family history of prostate cancer, black . . . [Full Text of this Article]

Source Information

From the Department of Urology, Memorial Sloan-Kettering Cancer Center, New York.

This article was published at www.nejm.org on June 24, 2003.

Related Letters:

Prevention of Prostate Cancer with Finasteride
Rubin M. A., Kantoff P. W., Roehrborn C. G., Burke H. B., Schwartz D. T., Ross R. K., Skinner E., Cote R. J., Lee S. C., Ellis R. J., Barzell W. E., Thompson I. M. Jr., Goodman P. J., Coltman C. A. Jr.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:1569-1572, Oct 16, 2003. Correspondence

This article has been cited by other articles:

• Logothetis, C. J., Schellhammer, P. F. (2008). High-Grade Prostate Cancer and the Prostate Cancer Prevention Trial. Cancer Prevention Research 1: 151-152 [Full Text]  
• Redman, M. W., Tangen, C. M., Goodman, P. J., Lucia, M. S., Coltman, C. A. Jr., Thompson, I. M. (2008). Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach. Cancer Prevention Research 1: 174-181 [Abstract] [Full Text]  
• Lucia, M. S., Epstein, J. I., Goodman, P. J., Darke, A. K., Reuter, V. E., Civantos, F., Tangen, C. M., Parnes, H. L., Lippman, S. M., La Rosa, F. G., Kattan, M. W., Crawford, E. D., Ford, L. G., Coltman, C. A. Jr, Thompson, I. M. (2007). Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial. JNCI J Natl Cancer Inst 99: 1375-1383 [Abstract] [Full Text]  
• Manassero, F., Erba, P., Mariani, G., Mogorovich, A., Giannarini, G., Selli, C. (2007). Metastatic Prostate Cancer After Orchiectomy, Radiotherapy, and Testosterone Replacement in a Patient With Bilateral Seminoma. J Androl 28: 10-12 [Full Text]  
• Ammar, H., Malani, A. K, Gupta, C. (2006). Benign prostatic hyperplasia: Caveat for finasteride should be discussed before prescribing. BMJ 333: 654-654 [Full Text]  
• Thompson, I. M., Chi, C., Ankerst, D. P., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., Coltman, C. A. Jr. (2006). Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer.. JNCI J Natl Cancer Inst 98: 1128-1133 [Abstract] [Full Text]  
• Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., Abate-Shen, C. (2006). Emergence of Androgen Independence at Early Stages of Prostate Cancer Progression in Nkx3.1; Pten Mice. Cancer Res. 66: 7929-7933 [Abstract] [Full Text]  
• Lotan, Y., Cadeddu, J. A., Lee, J. J., Roehrborn, C. G., Lippman, S. M. (2005). Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes. JCO 23: 1911-1920 [Abstract] [Full Text]  
• Cha, T.-L., Qiu, L., Chen, C.-T., Wen, Y., Hung, M.-C. (2005). Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth. Cancer Res. 65: 2287-2295 [Abstract] [Full Text]  
• Lippman, S. M., Goodman, P. J., Klein, E. A., Parnes, H. L., Thompson, I. M., Kristal, A. R., Santella, R. M., Probstfield, J. L., Moinpour, C. M., Albanes, D., Taylor, P. R., Minasian, L. M., Hoque, A., Thomas, S. M., Crowley, J. J., Gaziano, J. M., Stanford, J. L., Cook, E. D., Fleshner, N. E., Lieber, M. M., Walther, P. J., Khuri, F. R., Karp, D. D., Schwartz, G. G., Ford, L. G., Coltman, C. A. (2005). Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JNCI J Natl Cancer Inst 97: 94-102 [Abstract] [Full Text]  
• Parnes, H. L., Thompson, I. M., Ford, L. G. (2005). Prevention of Hormone-Related Cancers: Prostate Cancer. JCO 23: 368-377 [Abstract] [Full Text]  
• Rosner, W. (2004). Proscar and Propecia--A Therapeutic Perspective. J. Clin. Endocrinol. Metab. 89: 3096-3098 [Full Text]  
• Pitts, W. R. Jr (2004). Finasteride (Propecia) and the Promotion of High-grade Prostate Cancer. Arch Dermatol 140: 885-886 [Full Text]  
• Rubin, M. A., Kantoff, P. W., Roehrborn, C. G., Burke, H. B., Schwartz, D. T., Ross, R. K., Skinner, E., Cote, R. J., Lee, S. C., Ellis, R. J., Barzell, W. E., Thompson, I. M. Jr., Goodman, P. J., Coltman, C. A. Jr. (2003). Prevention of Prostate Cancer with Finasteride. NEJM 349: 1569-1572 [Full Text]  
• (2003). Does Finasteride Prevent Prostate Cancer?. Journal Watch Dermatology 2003: 9-9 [Full Text]  
• (2003). Does Finasteride Prevent Prostate Cancer?. JWatch General 2003: 1-1 [Full Text]